Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 325Lung Neoplasms 237Small Cell Lung Carcinoma 79Colorectal Neoplasms 30NSCLC 25Breast Neoplasms 22Neoplasms 16Adenocarcinoma of Lung 16Disease 15Neoplasm Metastasis 12Stomach Neoplasms 10Melanoma 10Ovarian Neoplasms 9Brain Neoplasms 9Uterine Cervical Neoplasms 8Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Pleural Effusion, Malignant 8Motor Activity 8Mesothelioma, Malignant 8Head and Neck Neoplasms 8Esophageal Neoplasms 7Endometrial Neoplasms 7Multiple Pulmonary Nodules 6Mesothelioma 6Carcinoma, Hepatocellular 6Thymoma 5Small Cell Lung Cancer Extensive Stage 5SCLC, Extensive Stage 5Recurrence 5

Interventions

ensartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × ALK-positive Advanced NSCLC × Thoracic × Clear all
NCT06785584 2025-01-21

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma :A Multicenter, Real-World Clinical Study

Fujian Medical University Union Hospital

Phase 4 Not yet recruiting
30 enrolled
Thoracic

ALK-positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡